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ABSTRACT
Objective Osteoarthritis (OA) has a strong genetic
component but the success of previous genome-wide
association studies (GWAS) has been restricted due to
insufﬁcient sample sizes and phenotype heterogeneity.
Our aim was to examine the effect of clinically relevant
endophenotyping according to site of maximal joint
space narrowing (maxJSN) and bone remodelling
response on GWAS signal detection in hip OA.
Methods A stratiﬁed GWAS meta-analysis was
conducted in 2118 radiographically deﬁned hip OA
cases and 6500 population-based controls. Signals were
followed up by analysing differential expression of
proximal genes for bone remodelling endophenotypes in
33 pairs of macroscopically intact and OA-affected
cartilage.
Results We report suggestive evidence (p<5×10−6) of
association at 6 variants with OA endophenotypes that
would have been missed by using presence of hip OA as
the disease end point. For example, in the analysis of
hip OA cases with superior maxJSN versus cases with
non-superior maxJSN we detected association with a
variant in the LRCH1 gene (rs754106, p=1.49×10−7,
OR (95% CIs) 0.70 (0.61 to 0.80)). In the comparison
of hypertrophic with non-hypertrophic OA the most
signiﬁcant variant was located between STT3B and
GADL1 (rs6766414, p=3.13×10−6, OR (95% CIs) 1.45
(1.24 to 1.69)). Both of these associations were fully
attenuated in non-stratiﬁed analyses of all hip OA cases
versus population controls (p>0.05). STT3B was
signiﬁcantly upregulated in OA-affected versus intact
cartilage, particularly in the analysis of hypertrophic and
normotrophic compared with atrophic bone remodelling
pattern (p=4.2×10−4).
Conclusions Our ﬁndings demonstrate that
stratiﬁcation of OA cases into more homogeneous
endophenotypes can identify genes of potential
functional importance otherwise obscured by disease
heterogeneity.
INTRODUCTION
Osteoarthritis (OA) is a phenotypically heteroge-
neous disease characterised by cartilage degener-
ation and bone remodelling within synovial joints,1
and affects 9 million people in the UK alone.2 The
heritable component to OA susceptibility is
estimated at 40%–65%,3–5 however fewer than 20
robustly associated genetic loci have been identiﬁed
to date explaining <10% of this heritability.6–18
These candidate gene and genome-wide association
studies (GWAS) used a simple dichotomous descrip-
tion of joint involvement that does not reﬂect the
heterogeneity of OA biology,19 with the exception
of the DOT1L association with hip OA in men that
was made by measurement of cartilage thickness.20
OA endophenotypes may be characterised on
plain radiographs by the pattern of joint involve-
ment and by the bone remodelling response to the
disease.21–23 At the hip, the site of maximum joint
space narrowing (maxJSN) can be classiﬁed as
superior, medial, axial or concentric.22 24 25 The
superior pattern is most common in men and is a
risk factor for disease progression.26 27 Medial
migration is more common in women and more
likely to occur bilaterally.26–30 The bone remodel-
ling response to OA also varies between indivi-
duals, and may be classiﬁed as atrophic (bony
attrition, cysts and a lack of osteophytes), normo-
trophic (osteophytes <grade 3) or hypertrophic
(osteophytes ≥grade 3±increased femoral head
size).23 Atrophic OA is associated with thinner tra-
beculae, lower bone volume and lower bone
mineral density than the hypertrophic or normo-
trophic patterns of OA.31 32 Atrophic OA is also
associated with faster disease progression, osteopor-
osis and with femoral head collapse.28 33 The risk
of severe hip OA is threefold greater in siblings of
index cases with an atrophic pattern of hip OA
compared with siblings whose index case had a
normotrophic or hypertrophic bone remodelling
response.27
Here, we applied these clinically relevant radio-
graphic endophenotypes to identify novel variants
that associate with hip OA in a subset of subjects
from the arcOGEN Study,14 the largest hip and
knee OA GWAS to date. We calculated the differ-
ences in statistical power achieved using this
approach versus a simple dichotomous description
of joint involvement. We investigated the effect of
using these endophenotype deﬁnitions on signal
detection for previously established hip OA loci.
Finally, we examined the expression levels of genes
highlighted in the association analysis in primary
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human chondrocytes taken from patients classiﬁed using the
same bone remodelling endophenotypes.
PATIENTS AND METHODS
Study populations and radiographic classiﬁcation
The hip OA subjects comprised 2118 unrelated individuals of
UK European ancestry participating in the arcOGEN Study, an
ethically approved study in which all subjects provided written,
informed consent prior to participation.14 All had radiographic
evidence of hip OA (Kellgren-Lawrence (KL) Score ≥2) on a
digitised anteroposterior radiograph of the affected joint.21 Hip
OA pattern was classiﬁed by the site of maxJSN as superior,
axial, medial or concentric using the Osteoarthritis Research
Society International (OARSI) atlas and the KL Score (table
1).21 22 The bone remodelling response was classiﬁed according
to the Bombelli and OARSI atlases as atrophic, normotrophic or
hypertrophic.22 23 Each radiograph was read independently by
two clinically trained observers (ST and EZen). Where discrep-
ancy existed between the observers, adjudication was made by
the senior clinical author ( JMW). The correlation between the
two primary observers was ‘very good’ for the axial and medial
JSN phenotypes (κ=0.85, 95% CI 0.82 to 0.88)34 and ‘good’
for the superior JSN phenotype (κ=0.7, 95% CI 0.67 to 0.73);
‘good’ for the atrophic remodelling phenotype (κ=0.64, 95%
CI 0.58 to 0.69) and ‘moderate’ for the hypertrophic phenotype
(κ=0.54, 95% CI 0.50 to 0.58).
Genotyping, imputation and association analyses
Genotypes were extracted from 1817 and 301 hip OA cases previ-
ously genotyped on Human 610-Quad and HumanOmniExpress
(Illumina, San Diego, USA) platforms, respectively (ﬁgure 1). The
controls comprised 6500 subjects previously included in the
arcOGEN GWAS: The Wellcome Trust Case Control Consortium
2 Study 1958 Birth Cohort, the UK National Blood Donor Service
and the Type 1 Diabetes Genetics Consortium.14 A 1000
Genomes Project-based imputation was conducted,35 36 and was
followed by stringent quality control excluding variants with
minor allele frequency (MAF)<0.01 and minor allele count <10
given the different sample sizes of the GWAS case cohorts,37
imputation information score <0.4 and by inspecting genotype
intensity plots 100 kb on either side of the top signals and
re-imputation of these regions of association.
Association analyses at ∼7 million variants were made under
an additive model (maximum likelihood ratio test,
SNPTESTv2.5). Our primary analyses comprised ﬁxed-effect
meta-analyses38 within OA cases stratiﬁed by site of maxJSN or
by bone remodelling response to identify variants exclusively
associated with these endophenotypes (table 1 and ﬁgure 1).
The axial and medial maxJSN groups were collapsed into one
(axial/medial) due to the small sample size in each of these cat-
egories. Promising signals were independently validated by de
novo genotyping using the MassARRAY iPLEX Gold assay
(Agena Bioscience GmbH, Hamburg, Germany).
In our secondary analyses the GWAS outputs for the stratiﬁed
hip OA cases against population-based controls were compared
with that achieved using a non-stratiﬁed GWAS of all hip OA
cases versus population-based controls. Power was calculated
using Quanto V.1.2.4 under the additive model39 at α=5×10−8,
and based on study-speciﬁc effect sizes and case-control ratios
identiﬁed in the Human 610-Quad GWAS. Similarly, the sample
size required to have 80% power to detect the associated signals
with genome-wide signiﬁcance (p=5×10−8) was estimated. To
calculate the sample size fold reduction afforded by the use of
precise phenotype deﬁnitions over an all hip OA versus controls
approach we ﬁxed the estimated sample size of hip OA cases
from inﬁnite to n=1 000 000.
Gene expression analysis
Gene expression proﬁles were examined in samples from the
RAAK Study (Research Arthritis and Articular Cartilage) from
individuals undergoing joint replacement surgery, as described
previously.40 Isolated RNA was prepared for hybridisation using
the Illumina TotalPrep RNA Ampliﬁcation Kit (Illumina, San
Diego, USA) onto Illumina HumanHT-12 v3 microarrays, with
each pair (OA-affected and intact) measured on the same chip.
Microarrays were read using an Illumina Beadarray 500GX
scanner and data were analysed in R statistical programming lan-
guage after quality checks using Illumina Beadstudio analysis
software (Illumina). Intensity values were normalised and
absence of large-scale between-chip effects was conﬁrmed using
the Globaltest-package.41 Probes that were not optimally mea-
sured were removed (detection p>0.05 in more than 50% of
the samples). All comparisons of the differential normalised
probe expression levels between intact and diseased OA chon-
drocytes were made in SPSS (V.23, IBM, New York, USA) using
the generalised estimation equations and corrected for age and
sex. A random effect for patient identity (ID) was included to
account for the structure of the data and correct for putative
correlations between intact and OA-affected articular cartilage
from the same joint.
Preoperative plain radiographs of the affected joint were
scored independently by two experienced readers ( JMTAM,
KH) to determine the OA subtype. Subsequently, osteophytes
and JSN were graded 0–3 for lateral and medial femur and tibia
(knee joints) and for inferior and superior femur and acetabu-
lum (hip joints) by consensus opinion using the OARSI atlas.22
RESULTS
Site of maxJSN association analysis
In the GWAS meta-analysis of hip OA cases with superior
maxJSN versus all other hip OA cases (see online
supplementary ﬁgure S1a), the most signiﬁcant association was
observed at rs754106 (MAF=0.46) in intron 1 of the LRCH1
(leucine-rich repeats and calponin homology domain containing
1) gene (T allele OR (95% CIs) 0.70 (0.61 to 0.80),
p=1.49×10−7 (table 2 and see online supplementary ﬁgure
S2a)), and was consistent across both cohorts (see online
supplementary table S1). In the GWAS meta-analysis of hip OA
cases with axial/medial maxJSN versus all other hip OA cases
(see online supplementary ﬁgure S1b), rs754106 was also the
most signiﬁcantly associated variant (p=3.66×10-7) but with
the effect of the T allele in the opposite direction, in keeping
with expectation (OR (95% CIs) 1.47 (1.27 to 1.70), table 2
and see online supplementary table S1).
In the association analyses of hip OA cases with superior
maxJSN versus population-based controls (see online
supplementary ﬁgure S3a) and of patients with hip OA with
axial/medial maxJSN versus population-based controls (see
online supplementary ﬁgure S3b), opposite directions of effect
were also observed for allele T: OR (95% CIs) 0.91 (0.84 to
0.99), p=0.034 compared with OR (95% CIs) 1.32 (1.14 to
1.52), p=1.39×10−4, respectively (see online supplementary
table S1). When all hip OA cases were analysed together versus
the same population-based control set, the signal was fully atte-
nuated (OR (95% CIs) 1.01 (0.93 to 1.08), p=0.89) (see online
supplementary table S1 and ﬁgure S3e).
The second most signiﬁcant ﬁnding in the superior maxJSN
stratum versus all other hip OA cases was observed at
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rs73023563 (MAF=0.19) located between CWC22
(spliceosome-associated protein homologue (S. Cerevisiae)) and
UBE2E3 (ubiquitin-conjugating enzyme E2E 3) (T allele OR
(95% CIs) 1.59 (1.33 to 1.91), p=6.59×10−7, table 2 and see
online supplementary ﬁgure S2b). The rs73023563 association
was also strong in the converse stratum (hip OA cases with
axial/medial maxJSN vs all other hip OA cases) with the oppos-
ite direction of effect (T allele OR (95% CIs) 0.61 (0.50 to
0.75), p=2.03×10−6). Its association in the analysis of axial/
medial maxJSN cases versus population-based controls was
equally strong (OR (95% CIs) 0.63 (0.52 to 0.78),
p=3.45×10−6), and was also fully attenuated in the all hip OA
analysis versus population-based controls analysis (OR (95%
CIs) 0.94 (0.86 to 1.03), p=0.21) (see online supplementary
table S1).
In the association analysis of hip OA with axial/medial
maxJSN versus all other hip OA cases the second most signiﬁ-
cant single nucleotide polymorphism (SNP) was rs17050727
(MAF=0.14), located between PRDM5 (PR domain containing
5) and MAD2L1 (mitotic arrest deﬁcient-like 1 (yeast), T allele
OR (95% CIs) 1.65 (1.35 to 2.01), p=6.87×10−7 (table 2, see
online supplementary table S1 and ﬁgure S2c). rs17050727
exhibited a similar pattern of association with the converse
stratum (superior maxJSN vs all other hip OA cases) as for the
variants described above; and its association was also fully atte-
nuated in the hip OA analysis versus population-based controls
analysis (OR (95% CIs) 1.00 (0.90 to 1.12), p=0.98, see online
supplementary table S1).
Adjustments for sex, height and body mass index (BMI) had
little effect on the association strength of the reported signals
Table 1 Patient characteristics
OA phenotype
arcOGEN_Illum610K
N (men/women)
arcOGEN_OmniExpress
N (men/women)
N total
(men/women)
Prevalence
(%)
Hip (KL Score ≥2) 1817 (776/1041) 301 (125/176) 2118 (901/1217) 100
Site of maximal joint space narrowing (pattern of femoral head migration within the acetabulum)
Axial 158 (34/124) 28 (5/23) 186 (39/147) 8.8
Medial 267 (69/198) 48 (10/38) 315 (79/236) 14.9
Superior 1265 (615/650) 204 (98/106) 1469 (713/756) 69.3
Concentric 127 (58/69) 21(12/9) 148 (70/78) 7.0
Bone remodelling response
Atrophic 267 (113/154) 18* (8/10) 285 (121/164) 13.4
Hypertrophic 531 (239/292) 106 (46/60) 637 (285/352) 30.1
Normotrophic 1019 (424/595) 177(71/106) 1196(495/701) 56.5
*These individuals were not used as cases in the within-OA genome-wide association analysis of the arcOGEN OmniExpress data set due to the small sample number.
KL, Kellgren-Lawrence; OA, osteoarthritis.
Figure 1 Genome-wide association study design, showing primary and secondary analyses. svns, superior joint space narrowing versus
non-superior; amvnam, axial/medial joint space narrowing versus non-axial/medial; hvnh, hypertrophic bone response versus non-hypertrophic; avna,
atrophic bone response versus non-atrophic; svcon, superior joint space narrowing versus population-based controls; amvcon, axial/medial joint
space narrowing versus population-based controls; hvcon, hypertrophic bone response versus population-based controls; avcon, atrophic bone
response versus population-based controls; hipvcon, hip osteoarthritis (OA) versus population-based controls.
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(see online supplementary table S2). Following validation
experiments by de novo genotyping we found 100% genotype
and minor allele concordance with GWAS genotypes of
overlapping samples at rs754106 (see online supplementary
table S3).
Bone remodelling response association analysis
In the GWAS meta-analysis of hypertrophic versus
no-hypertrophic hip OA cases (see online supplementary ﬁgure
S1c) the most signiﬁcant SNP was rs6766414 (MAF=0.24)
located between STT3B (subunit of the oligosaccharyltransferase
complex (catalytic)) and GADL1 (glutamate decarboxylase-like
1), G allele OR (95% CIs) 1.45 (1.24 to 1.69), p=3.13×10−6
(table 1 and see online supplementary ﬁgure S2d). We also
found evidence of association in the hypertrophic OA versus
population-based controls analysis, G allele OR (95% CIs) 1.25
(1.09 to 1.44), p=1.74×10−3 (see online supplementary table
S1 and ﬁgure S3c). In the analysis of hip OA cases versus
population-based controls the signal was fully attenuated (OR
(95% CIs) 1.00 (0.92 to 1.09), p=0.98) (see online
supplementary table S1).
The second most signiﬁcant replicating SNP in the hyper-
trophic versus non-hypertrophic stratum, rs61837881
(MAF=0.24) located between C1orf65 and CAPN8 (calpain 8),
was associated exclusively with the hypertrophic response (allele
C: OR (95% CIs) 1.44 (1.23 to 1.68), p=4.56×10−6, see
online supplementary ﬁgure S2e) and was fully attenuated in the
analysis of hip OA versus population-based controls (OR (95%
CIs) 1.06 (0.97 to 1.15), p=0.23, table 2 and see online
supplementary table S1). Adjustment for sex, height and BMI
had little effect on the association strength of the reported var-
iants (table 2 and see online supplementary table S2).
In the GWAS of atrophic versus non-atrophic OA (see online
supplementary ﬁgure S1d), the most signiﬁcant association was
observed at rs16869403, which resides within the gene encod-
ing the G protein-coupled receptor 98 (GPR98) (MAF=0.10,
allele G OR (95% CI) 2.11 (1.61 to 2.75), p=1.37×10−7, see
online supplementary ﬁgure S2f and table S1). The strength of
association was similar in the analysis of atrophic OA cases
versus population-based controls (OR (95% CI) 1.93 (1.52 to
2.46), p=4.14×10−7, see online supplementary table S1 and
ﬁgure S3d). This association was fully attenuated in the non-
stratiﬁed hip OA versus population-based controls analysis (OR
(95% CI) 1.05 (0.93 to 1.19), p=0.43; see online
supplementary table S1). Genotype and minor allele concord-
ance between typed and imputed genotypes at this SNP
were 99% and 97%, respectively (see online supplementary
table S3).
Power gains
Power increases substantially in the within-OA analyses com-
pared with the non-stratiﬁed hip OA versus population-based
controls analysis (table 3). Small to modest power increases are
observed in the stratiﬁed OA cases versus population-based con-
trols analyses compared with the non-stratiﬁed hip OA versus
population-based controls analysis. The decrease in sample size
required to reach genome-wide signiﬁcance for an analysis
within OA cases over the non-stratiﬁed hip OA versus
population-based controls analysis ranged from 41-fold to
286-fold. The decrease in sample size between stratiﬁed hip OA
versus population-based controls analyses over the non-stratiﬁed
hip OA versus population-based controls analysis ranged from
1-fold to >240-fold.T
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Established hip OA loci
The strength of association of the 10 established hip OA suscep-
tibility loci in Europeans18 was examined in each of the hip OA
strata (see online supplementary table S4). Here, the risk allele
of rs12982744 in DOTL1 associated with hip OA
(p=3.06×10−4, OR (95% CIs) 1.15 (1.07 to 1.24)) but the
most signiﬁcant association was observed in the analysis of hip
OA with superior maxJSN versus population-based controls
(p=8.17×10−6, OR (95% CIs) 1.22 (1.12 to 1.34)) (see online
supplementary table S4). Further corroboration of this stratum-
speciﬁc association comes from the within-OA GWAS analyses
of the hip OA cases with superior maxJSN versus all other hip
OA cases (p=7.58×10−3, OR (95% CIs) 1.22 (1.06 to 1.42);
and converse stratum p=1.13×10−2, OR (95% CIs) 0.81 (0.69
to 0.95)). The effect size differed between men and women
both in our hip OA versus population-based control analysis
(men p=8.92×10−6, OR (95% CIs) 1.30 (1.16 to 1.46);
women p=0.32, OR (95% CIs) 1.05 (0.95 to 1.17)), and in the
superior maxJSN versus population-based controls analysis
(men p=5.20×10−6, OR (95% CIs) 1.35 (1.18 to 1.53);
women p=0.07, OR (95% CIs) 1.12 (0.99 to 1.27)). This sug-
gests that the sex disparity of effects at the DOT1L locus is not
driven by the differences in prevalence of different JSN patterns
between the two sexes.
Five other index SNPs (rs9350591, rs10948172, rs11177,
rs4836732, rs6094710) also exhibited similar or lower p values
and higher ORs in endophenotype-based association analyses
than in the hip OA versus population-based controls analysis,
despite the decrease in case sample size (ranging from 30% to
77%) (see online supplementary table S4). However, unlike the
DOT1L variant, none of these showed an association that was
strengthened enough to compensate for the multiple compari-
sons performed.
Gene expression analyses in articular cartilage
The expression levels of 10 genes located near variants high-
lighted in the bone remodelling stratiﬁed GWAS (GRP98 and
ADGVR1 for rs16869403; STT3B, GADL1, OSBPL10, THRAP3
and TGFBR2 for rs6766414; and C1orf65, CAPN8 and SUSD4
for rs61837881) were examined in macroscopically intact and
OA-affected articular cartilage (n=33 pairs from the RAAK
Study, 6 with an atrophic, 19 with a normotrophic and 8 with a
hypertrophic phenotype). We observed robust expression for
SUSD4, STT3B, OSBPL10 and TGFBR2, with mean normalised
probe level values of 7.9, 7.8, 8.4 and 11.5, respectively. Of
these genes, only STT3B showed differential expression with
respect to the disease process, with signiﬁcant upregulation in
OA-affected versus intact cartilage independent of joint site, par-
ticularly in patients with hypertrophic/normotrophic OA (fold
change=1.30, p=4.23×10−4; ﬁgure 2). When the genotypes of
rs6766414 (TT and TG) were tested, a signiﬁcantly lower
expression of STT3B in lesioned OA cartilage was observed
among carriers of allele G (n=9 heterozygotes-no homozygotes
for the G allele were present in our data) compared with
Table 3 Power gains associated with dichotomous versus specific radiographic endophenotype descriptors
Study parameters Estimated parameters
SNP Definition of cases Definition of controls
N
cases
N
controls EAF OR
Power
(%) N cases N controls N total
rs754106 Hip OA with superior JSN Hip OA with non-superior JSN 1265 552 0.54 0.72 18.45 2416 1054 3470
Hip OA with superior JSN Population-based 1265 6500 0.54 0.91 0.05 10 669 54 821 65 490
Hip OA Population-based 1817 6500 0.54 1.01 0.00 >1 000 000 >3 577 325 >4 577 325
rs73023563 Hip OA with superior JSN Hip OA with non-superior JSN 1265 552 0.19 1.63 57.78 1571 686 2257
Hip OA with superior JSN Population-based 1265 6500 0.20 1.07 0.00 31 513 161 925 193 438
Hip OA Population-based 1817 6500 0.19 0.94 0.00 43 995 157 384 201 379
rs17050727 Hip OA with axial/medial
JSN
Hip OA with non-axial/medial
JSN
425 1392 0.14 1.65 28.62 705 2309 3014
Hip OA with axial/medial
JSN
Population-based 425 6500 0.14 1.43 4.89 1168 17 864 19 032
Hip OA Population-based 1817 6500 0.14 1.00 0.00 ∞ ∞ ∞
rs6766414 Hip OA with hypertrophic
response
Hip OA with non-hypertrophic
response
531 1286 0.24 1.42 12.40 1139 2758 3897
Hip OA with hypertrophic
response
Population-based 531 6500 0.24 1.25 0.92 2199 26 918 29 117
Hip OA Population-based 1817 6500 0.24 1.00 0.00 ∞ ∞ ∞
rs61837881 Hip OA with hypertrophic
response
Hip OA with non-hypertrophic
response
531 1286 0.24 1.39 7.69 1298 3144 4442
Hip OA with hypertrophic
response
Population-based 531 6500 0.24 1.33 7.15 1323 16 195 17 518
Hip OA Population-based 1817 6500 0.24 1.06 0.00 40 187 143 762 183 949
rs16869403 Hip OA with atrophic
response
Hip OA with non-atrophic
response
267 1550 0.10 2.11 58.36 330 1916 2246
Hip OA with atrophic
response
Population-based 267 6500 0.10 1.93 42.25 383 9324 9707
Hip OA Population-based 1817 6500 0.10 1.05 0.00 115 540 413 324 528 864
For each variant and stratum we present power (%) based on study-specific effect size, effect allele frequency and case/control ratio from the GWAS on Illumina610k. Similarly we
estimated the sample size required to have 80% power to detect the associated signals with genome-wide significance (p=5×10−8).
EAF, effect allele frequency; GWAS, genome-wide association studies; JSN, joint space narrowing; OA, osteoarthritis; SNP, single nucleotide polymorphism.
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homozygous individuals for allele T (n=15; fold change=0.79,
p=0.021). Moreover, in the hypertrophic/normotrophic OA
stratum, the upregulation of STT3B expression in OA-affected
versus intact cartilage appeared to be mitigated among indivi-
duals heterozygous for allele G of rs6766414 (n=6), yet
remained signiﬁcantly upregulated among homozygous carriers
(n=14) of allele T (fold change=1.4, p=2.8×10−4, ﬁgure 3).
DISCUSSION
We applied clinical radiographic endophenotypes to stratify
genome-wide association analysis of hip OA and identify six
putative associations (p<5×10−6). For the strongest signals in
both endophenotypes we observe consistent effects across com-
plementary strata both in the primary analysis and against
population-based controls in the secondary analyses. These
signals were all fully attenuated in the non-stratiﬁed analyses
against the population-based controls, consistent with our
hypothesis that this stratiﬁcation approach increases the sensitiv-
ity of signal detection.
rs754106, which showed the strongest association with
pattern of maxJSN, resides in intron 1 of the LRCH1/CHDC1
gene whose function has not been well characterised. However,
replicating associations with knee OA at variants spanning
intron 1 of LRCH1 have been identiﬁed in samples of European
descent.42 rs6766414, which showed the strongest association
with bone remodelling response, is located between STT3B and
GADL1. STT3B mediates both co-translational and post-
translational N-glycosylation of proteins and GO terms asso-
ciated with this gene include glycoprotein catabolic process.43
STT3B encodes a catalytic subunit of the N-oligosaccaryl trans-
ferase complex,44 suggesting that altered glycosylation in
OA-affected cartilage mitigates protein folding and affects inter-
molecular interactions.45 Thus we hypothesise that the upregu-
lation of STT3B is a beneﬁcial response among hypertrophic
cases.
This study also has limitations. While the interobserver agree-
ment of the radiographic classiﬁers supports the approach
taken, differences in calling between observers does impact on
the overall sensitivity of both the genetic association and expres-
sion analyses. Although the identiﬁed loci did not meet the
Bonferroni-adjusted genome-wide signiﬁcance threshold of
p<5×10−9 used because of the multiple discovery association
analyses conducted, the putative association of variants with
speciﬁc endophenotypes corroborated by substantial or full
attenuation in other strata warrants replication and further func-
tional investigation.
The hypothesis that stratiﬁcation of cases into distinct
endophenotypic categories provides a more direct link to the
genetic basis of OA has not been previously tested systematically.
However, this approach has been successfully applied to
better understand disease biology in related complex traits,
including joint shape and pain.46–50 The results of our analyses
show that, if further replication is targeted to the speciﬁc
OA endophenotypes, study power may improve from nearly
0% in the traditional approach to 80% in a sample size
of <5000 cases. We used post hoc power calculations,
applying the observed variances from the study population of
interest to exemplify the difference in the statistical power of
the tests we performed. Such calculations have limitations,
but are useful in designing follow-up studies and in
conducting meta-analyses. We address one limitation in inter-
preting post hoc power calculations, ascertainment bias, by
examining the actual summary statistics of the previously estab-
lished genome-wide signiﬁcant locus (DOT1L) associated with
JSN. We ﬁnd that the index SNP is more strongly associated in
hip OA cases with superior JSN than in the non-stratiﬁed hip
OA versus controls analyses (p=8×10−6 and p=3×10−4,
respectively). As more precise phenotype deﬁnitions are accrued
in the ﬁeld and future replication is targeted to the speciﬁc
endophenotype, the strength of the observed associations may
increase and the power burden of multiple testing may be
resolved. Our ﬁndings demonstrate that stratiﬁcation of OA
cases into more homogeneous endophenotypes can identify
genes of potential functional importance otherwise obscured by
disease heterogeneity.
Figure 3 Box plots of the expression levels of STT3B in patients with
hypertrophic/normotrophic osteoarthritis (OA), plotted as mean
normalised probe level values, in macroscopically intact (green boxes)
and diseased (red boxes) OA articular cartilage stratiﬁed by carriers of
the G allele (heterozygous individuals plotted since no homozygotes for
the G allele were present in our data) and by non-carriers at
rs6766414. Grey dots show values of each individual sample.
Figure 2 Box plots of the expression levels of STT3B plotted as the
mean normalised probe level values in macroscopically intact (green
boxes) and diseased (red boxes) osteoarthritis (OA) articular cartilage of
patients with atrophic (n=6) and normotrophic (n=27) OA. Grey dots
show values of each individual sample.
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